NTHIHealthcare · BiotechnologyThe 3 Wall Street analysts covering NeOnc Technologies Holdings, Inc. hold a median 12-month price target of $15 — +219.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 20 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores NeOnc Technologies Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (74): Smaller than most of the companies we track.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on NTHI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +219.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 May 2026 | BTIG | Reiterates | Buy | $15 |
| 19 May 2026 | Alliance Global Partners | Initiates | Buy | $13 |
| 18 May 2026 | Maxim Group | Initiates | Buy | — |
| 24 Apr 2026 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NTHI appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, NeOnc Technologies Holdings, Inc. returned −19.4% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 1% of US stocks
Cheaper than 97% of US stocks
Cheaper than 71% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
NeOnc Technologies Holdings, Inc. has a market value of $121.3M and an enterprise value of $117.7M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$38.6M.
Free cash flow in the twelve months to 31 Mar 2026: −$22.2M.
Trailing P/E: −1.5×; forward P/E: −4.6× — the forward figure prices analyst consensus estimates, not reported earnings.
NeOnc Technologies Holdings, Inc. employs 5 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| NTHINeOnc Technologies Holdings, Inc. | $121.3M | 20 |
| ENGNenGene Therapeutics, Inc. | $114.9M | 27 |
| COYACoya Therapeutics, Inc. | $114.2M | 60 |
| SEERSeer, Inc. (California) | $114.2M | 71 |
| RANIRani Therapeutics Holdings, Inc. | $120.0M | 64 |
| NAUTNautilus Biotechnology, Inc. | $121.3M | 55 |
| HURATuHURA Biosciences, Inc. | $121.4M | 18 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own NeOnc Technologies Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
NeOnc Technologies Holdings CEO Amir Heshmatpour purchased additional NTHI shares on the open market, buying 12,000 shares on August 14 at an average price of $3.7883 and 3,000 shares on August 17 at an average price of $4.3733, according to Form 4 filings.
Why it matters — NTHI watchers would care because continued insider buying by the CEO may signal confidence in the company's prospects.
GlobeNewsWire highlighted NeOnc Technologies Holdings (NTHI) as one of the Nasdaq stories gaining attention, citing the company's Phase 2a clinical data update as the catalyst.
Why it matters — NTHI watchers would care because the report signals growing market interest in the company's Phase 2a clinical update.
NeOnc Technologies (NASDAQ:NTHI) announced Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma, which the company views as a breakthrough. The article notes these results add new significance to its Nasdaq Global Market listing.
Why it matters — A NTHI watcher would care because the Phase 2a results for NEO100 represent a potentially important clinical milestone for the company's lead candidate.
Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI). The announcement, released August 13, 2026, confirms the coverage update but provides no further details.
Why it matters — A NTHI watcher would care because a research firm's updated coverage is a routine yet notable development for following the company.
NeOnc Technologies Holdings highlighted human clinical evidence for its non-invasive intranasal delivery strategy, designed to reach the brain without relying on conventional systemic delivery across the blood-brain barrier. Company filings describe NEO100 as an intranasally administered formulation of purified perillyl alcohol, with intranasal delivery listed among several approaches being investigated to overcome the blood-brain barrier.
Why it matters — NTHI watchers would care because this points to a broader patent-protected delivery platform beyond the company's single cancer drug candidate.
The 3 Wall Street analysts covering NeOnc Technologies Holdings, Inc. have a median 12-month price target of $15, with estimates ranging from $13 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering NeOnc Technologies Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, NeOnc Technologies Holdings, Inc. ranks 20 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +219.8% from the last close, and Ticker Nerd's factor model ranks NeOnc Technologies Holdings, Inc. 20 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering NeOnc Technologies Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTHI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $13 to $20 over the next 12 months.
NeOnc Technologies Holdings, Inc. returned -19.4% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
NeonC Technologies Holdings is a versatile entity operating in the technology sector. Primarily focused on driving innovation, the company develops cutting-edge software solutions designed to enhance operational efficiencies across various industries.
The most recent item we track (GlobeNewsWire, 18 Aug 2026): "NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't". NeOnc Technologies Holdings CEO Amir Heshmatpour purchased additional NTHI shares on the open market, buying 12,000 shares on August 14 at an average price of $3.7883 and 3,000 shares on August 17 at an average price of $4.3733, according to Form 4 filings.
NeonC Technologies Holdings is a versatile entity operating in the technology sector. Primarily focused on driving innovation, the company develops cutting-edge software solutions designed to enhance operational efficiencies across various industries. Leveraging advanced technologies such as artificial intelligence and machine learning, NeonC Technologies targets sectors including healthcare, finance, and logistics, providing tailor-made solutions that streamline complex processes. The company's commitment to research and development positions it as a significant player in the digital transformation landscape, fostering technological advancements and enabling organizations to adapt to rapidly changing market demands. This dedication not only underscores its role in pushing technological boundaries but also in bolstering the overall growth of the tech industry.
CEO Mr. Amir Farrokh Heshmatpour · 5 employees · United States · https://www.neonc.com
